Literature DB >> 18616691

A review of adherence to drug therapy in patients with overactive bladder.

Ramandeep K Basra1, Adrian Wagg, Christopher Chapple, Linda Cardozo, David Castro-Diaz, Montserrat Espuna Pons, Mike Kirby, Ian Milsom, Mark Vierhout, Philip Van Kerrebroeck, Con Kelleher.   

Abstract

Drug therapy for overactive bladder (OAB) is associated with improvements in symptoms and quality of life, but the short- and long-term adherence and persistence is suboptimal. In this review we outline methods of measuring, and factors affecting, adherence to pharmacotherapy in patients with OAB. Clinical practice suggests that adherence rates reported in clinical trials are much greater than in real practice. Factors affecting adherence include psychological and social variables that might alter patients' perception of the benefits of taking medication, and the effect of comorbidity and polypharmacy. Whilst there is some evidence that lack of efficacy and side-effects are contributory, these additional factors are also important.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18616691     DOI: 10.1111/j.1464-410X.2008.07769.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  46 in total

Review 1.  Selection of ideal candidates for neuromodulation in refractory overactive bladder.

Authors:  Ravi Kacker; Anurag K Das
Journal:  Curr Urol Rep       Date:  2010-11       Impact factor: 3.092

2.  Percutaneous tibial nerve stimulation and overactive bladder.

Authors:  Kamran P Sajadi; Howard B Goldman
Journal:  Curr Urol Rep       Date:  2010-09       Impact factor: 3.092

3.  Time-to-effect with darifenacin in overactive bladder: a pooled analysis.

Authors:  Vik Khullar; Jenelle Foote; Yodit Seifu; Mathias Egermark
Journal:  Int Urogynecol J       Date:  2011-10-18       Impact factor: 2.894

Review 4.  Factors influencing efficacy endpoints in clinical trials for new oral medicinal treatments for overactive bladder: a systematic literature review and meta-analysis.

Authors:  Shingo Iino; Masayuki Kaneko; Mamoru Narukawa
Journal:  Int Urol Nephrol       Date:  2018-04-12       Impact factor: 2.370

Review 5.  Patient-reported outcomes and different approaches to urinary parameters in overactive bladder: what should we measure?

Authors:  Vik Khullar
Journal:  Int Urogynecol J       Date:  2011-10-20       Impact factor: 2.894

6.  To clamp or not to clamp? Bladder management by suprapubic catheterization in patients with neurogenic bladder dysfunction.

Authors:  Jürgen Pannek; Konrad Göcking; Ulf Bersch
Journal:  World J Urol       Date:  2010-01-05       Impact factor: 4.226

Review 7.  Role of sacral neuromodulation in modern urogynaecology practice: a review of recent literature.

Authors:  Samina Tahseen
Journal:  Int Urogynecol J       Date:  2018-01-04       Impact factor: 2.894

Review 8.  Clinical pharmacokinetics and pharmacodynamics of solifenacin.

Authors:  Oxana Doroshyenko; Uwe Fuhr
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

9.  [Neurogenic or idiopathic destrusor overactivity after failed antimuscarinic treatment : clinical value of external temporary electrostimulation].

Authors:  J Pannek; S Janek; J Noldus
Journal:  Urologe A       Date:  2010-04       Impact factor: 0.639

Review 10.  The potential role of stem cells in the treatment of urinary incontinence.

Authors:  Christine Tran; Margot S Damaser
Journal:  Ther Adv Urol       Date:  2015-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.